このエントリーをはてなブックマークに追加
ID 52936
タイトル(別表記)
Molecular target therapies in rheumatic diseases
フルテキストURL
Thumnail 126_227.pdf 332 KB
著者
若林 宏 岡山大学大学院医歯薬学総合研究科 腎・免疫・内分泌代謝内科学
キーワード
リウマチ性疾患
自己免疫疾患
生物学的製剤
分子標的薬
備考
特集 (Feature Articles)
出版物タイトル
岡山医学会雑誌
発行日
2014-12-01
126巻
3号
出版者
岡山医学会
出版者(別表記)
Okayama Medical Association
開始ページ
227
終了ページ
230
ISSN
0030-1558
NCID
AN00032489
資料タイプ
学術雑誌論文
OAI-PMH Set
岡山大学
言語
Japanese
著作権者
Copyright (c) 2014 岡山医学会
論文のバージョン
publisher
査読
有り
DOI
NAID
Sort Key
9
Eprints Journal Name
joma
参考文献
1) Takeuchi T, Miyasaka N, Tatsuki Y, Yano T, Yoshinari T, Abe T, Koike T : Baseline tumour necrosis factor alpha levels predict the necessity for dose escalation of infliximab therapy in patients with rheumatoid arthritis. Ann Rheum Dis (2011) 70, 1208-1215.
2) Takeuchi T, Yamanaka H, Ishiguro N, Miyasaka N, Mukai M, Matsubara T, Uchida S, Akama H, Kupper H, Arora V, Tanaka Y : Adalimumab, a human anti-TNF monoclonal antibody, outcome study for the prevention of joint damage in Japanese patients with early rheumatoid arthritis : the HOPEFUL 1 study. Ann Rheum Dis (2014) 73, 536-543.
3) Palframan R, Airey M, Moore A, Vugler A, Nesbitt A : Use of biofluorescence imaging to compare the distribution of certolizumab pegol, adalimumab, and infliximab in the inflamed paws of mice with collagen-induced arthritis. J Immunol Methods (2009) 348, 36-41.
4) Singh JA, Christensen R, Wells GA, Suarez-Almazor ME, Buchbinder R, Lopez-Olivo MA, Ghogomu ET, Tugwell P : A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis : a Cochrane overview. CMAJ (2009) 181, 787-796.
5) Dougados M, Kissel K, Sheeran T, Tak PP, Conaghan PG, Mola EM, Schett G, Amital H, Navarro-Sarabia F, Hou A, Bernasconi C, Huizinga TW : Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders : 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY). Ann Rheum Dis (2013) 72, 43-50.
6) Axmann R, Herman S, Zaiss M, Franz S, Polzer K, Zwerina J, Herrmann M, Smolen J, Schett G : CTLA-4 directly inhibits osteoclast formation. Ann Rheum Dis (2008) 67, 1603-1609.
7) Ottaviani S, Moltó A, Ea HK, Neveu S, Gill G, Brunier L, Palazzo E, Meyer O, Richette P, Bardin T, Allanore Y, Lioté F, et al. : Efficacy of anakinra in gouty arthritis : a retrospective study of 40 cases. Arthritis Res Ther (2013) 15, R123.
8) Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, Kallenberg CG, St Clair EW, Turkiewicz A, Tchao NK, Webber L, Ding L, et al. : Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med (2010) 363, 221-232.
9) Mukhtyar C, Guillevin L, Cid MC, Dasgupta B, de Groot K, Gross W, Hauser T, Hellmich B, Jayne D, Kallenberg CG, Merkel PA, Raspe H, et al. : EULAR recommenda-tions for the management of primary small and medium vessel vasculitis. Ann Rheum Dis (2009) 68, 310-317.